The present invention relates to a pharmaceutical composition for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide bound to parathyroid hormone (PTH) or a fragment thereof. More particularly, the present invention relates to a pharmaceutical composition and biomaterial for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide represented by an amino acid sequence of SEQ ID NO. 3 bound to parathyroid hormone (PTH) or a fragment thereof represented by an amino acid sequence of SEQ ID NO. 4 or 5. The fusion peptide can improve effects of PTH by selectively binding to bone tissue and can reduce administration frequency by increasing the half-life. The fusion peptide can be used as a subcutaneous or intravenous injection-type pharmaceutical composition for treating osteoporosis and fracture, and can be used in combination with a medical device for tissue recovery to increase formation of bone tissue. In addition, when the fusion peptide is bound to the surface of dental and orthopedic medical devices, transplantation stability of the medical device can be improved through improved osseointegration between the medical device and new bone.

The invention is a composition comprising a biodegradable polymer and an additional component, said component comprising a cell, protein or drug, i.e. a therapeutic agent. The biodegradable polymer can change quality upon contact with a physiological parameter such as temperature or pH that causes, for example, a liquid polymer to gel or harden. The degradation of the polymer can be controlled to suit a tissue regeneration or wound healing time course.

This invention provides a process of obtaining a functional dermal substitute from decellularized amniotic membrane from placenta in combination with mammalian keratinocytes and its use as a tissue regeneration agent of skin, which the process for the generation of an artificial skin graft in the laboratory using specialized techniques in biotechnology such as the mammalian cells culture, preferably human, in which keratinocytes are cultured in aseptic conditions that form part of the epidermal layer of the skin, which are combined with a mesh rich in collagen which is obtained from cells that compose the structure of the skin in combination with the amniotic membrane of the placenta to generate two layers that can be used in burn patients or with skin lesions. Additionally, this technology considerably reduces the cost of treatment compared to the cost of current methods such as skin graft treatments (autografts or allograft) and the result of this process is a prompt cellular reorganization, remodeling, and re-epithelization of the wound resulting in the formation of new skin tissue and avoiding the formation of fibrotic tissue that results from contraction muscle.

This invention relates to the field of surgical implants, and in particular to a method of treating biomedical material, and more particularly bioprosthetic heart valves and tracheas, to mitigate calcification when implanted in a mammalian body.

An implantable tissue stabilizing structure for regenerating damaged muscle in situ by enabling mass migration of muscle precursor cells into the damaged muscle. The structure is formed by a plurality of singular monofilament thread sections, which are separated by a plurality of void spaces that define linear distances between the threads. The maximal diameter of the threads is proportional to the linear distance, such that for linear distance less than 1 millimeter the maximal threads diameter is 40 microns, for linear distance from 1 to 2 millimeters the maximal diameter is 120 microns, for linear distance from 2 to 5 millimeters the maximal diameter is 400 microns, for linear distance from 10 to 20 millimeters the maximal diameter is 2.5 millimeters, and for linear distance of 40 millimeters and greater the thread sections maximal diameter is 10 millimeters.

A tissue construct is provided that comprises a pancreas derived microvessel fragment and a pancreatic islet cell. The pancreas derived microvessel fragment and the pancreatic islet cell can be incorporated into a biocompatible medium. Tissue constructs can be comprised of other cells, such as stem cells, combined with the pancreas derived microvascular fragment. Methods for isolating microvessel fragments from a pancreas are also provided and include enzymatic digestion of pancreatic tissue and separation of microvessel fragments from endocrine and exocrine tissue. Methods for treating diabetes are further provided and include administration of the tissue constructs.

The present invention disclosed a process to coat the surface of flexible polymeric implant with biocompatible polymer such that the coating does not crack when the implant is subjected to mechanical forces such as tension, torsion or bending while retaining the inherent properties of the coated polymer.

The invention provides a method for delivering cells across the surface of a tissue, the method comprising distributing the cells on and/or within a biomaterial to form a cell bandage and applying the cell bandage to the surface, wherein, after application of the cell bandage to the surface of the tissue, the cells are released from the cell bandage. Further provided is a method for bonding two or more tissues, the method comprising providing a cell bandage in intimate contact with the surfaces to be joined, wherein the cell bandage comprises a biomaterial, said biomaterial having cells distributed on and/or within it.

Methods and devices are provided for preparing and implanting tissue scaffolds. Various embodiments of scribing tools are provided that are configured to mark one or more predetermined shapes around a defect site in tissue. The shape or shapes marked in tissue can be used to cut a tissue scaffold having a shape that matches the shape or shapes marked in tissue. In one embodiment, the scribing tool used to mark a shape in tissue can also be used to cut the tissue scaffold.

A method for preparing a supplement from mesenchymal cell cultures of Wharton's jelly including factors to favor the culture growth of cells from cutaneous system, in vitro, and to methods for producing epidermal, dermal, or cutaneous equivalents, and which may also be used as supplement for the proliferation and activation of autologous fibroblasts for subsequent intradcrmal use.